| Long-acting oral phosphodiesterase inhibition preconditions against reperfusion injury in an experimental lung transplantation model. | |
| | |
MedLine Citation:
|
PMID: 19379999 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: Ischemia-reperfusion injury remains a devastating complication of lung transplantation. Phosphodiesterase inhibitors have been shown to precondition tissues against ischemia-reperfusion injury. Little is known, however, about the utility of phosphodiesterase inhibition in reperfusion injury after lung transplantation. We evaluated the long-acting phosphodiesterase-5 inhibitor, tadalafil, in an ex vivo lung transplant model. METHODS: New Zealand White rabbits (4 kg), were given oral tadalafil (n = 11) 24 hours before lung harvest and compared with rabbits given oral vehicle alone (n = 11). Lungs were recovered with Perfadex solution (Vitrolife, Kungsbacka, Sweden) and cold stored for 18 hours. After storage, lung blocks were reperfused with donor rabbit blood in an ex vivo apparatus. Pulmonary artery pressures were recorded with serial arterial and venous blood gas sampling and animals served as their own controls. Phosphodiesterase-5 and protein kinase G tissue activity assays confirmed drug effects. Luminol chemiluminescence assay was used to measure reactive oxygen species and levels of endothelial and inducible nitric oxide synthase were measured. RESULTS: Extended cold storage, followed by reperfusion produced a consistent reproducible decrease in oxygenation and increase in pulmonary pressure. Tadalafil-treated animals exhibited greater Pao(2) throughout the course of reperfusion (P = .001) Mean pulmonary artery pressure was lower in tadalafil-treated animals (22 vs 40 mm Hg; P = .04). Phosphodiesterase-5 activity was decreased (143 +/- 8 vs 205 +/- 32 mP; P < .001) with protein kinase G activity increased (25 +/- 12 vs 12 +/- 2.4 fU/microg; P = .01) in the experimental group confirming that oral pretreatment resulted in active phosphodiesterase inhibition in the lung tissue. Reactive oxygen species (as measured by luminol activity) were decreased in tadalafil-treated animals (7.8 +/- 1.5 vs 10.2 +/- 1.2 relative light units; P = .003). CONCLUSIONS: Our experimental model demonstrates that oral donor pretreatment with a long-acting phosphodiesterase inhibitor is an effective strategy for improving pulmonary performance after reperfusion. Importantly, phosphodiesterase enzymes and their downstream effectors may play a critical role in reperfusion injury after lung transplantation. |
| | |
Authors:
|
Eric S Weiss; Hunter C Champion; Jason A Williams; William A Baumgartner; Ashish S Shah |
Related Documents
:
|
8842509 - Beneficial effects of felodipine on myocardial and coronary function during low-flow is... 11068179 - Glycogen turnover and anaplerosis in preconditioned rat hearts. 22595449 - The evolving role of β-adrenergic receptor blockers in managing hypertension. 12617989 - Influence of antithrombin on ischemia/reperfusion injury in the isolated blood-free per... 1539719 - Protection from reperfusion injury by preconditioning hearts does not involve increased... 3544349 - Inhibition of thromboxane a2 production does not improve post-ischemic brain hypoperfus... 17117139 - Intraperitoneal administration of hyperbarically oxygenated perfluorochemical enhances ... 2699419 - Custom-fabricated interfaces for intermittent positive pressure ventilation. 7015219 - Timolol. canadian multicenter study. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2009-03-17 |
Journal Detail:
|
Title: The Journal of thoracic and cardiovascular surgery Volume: 137 ISSN: 1097-685X ISO Abbreviation: J. Thorac. Cardiovasc. Surg. Publication Date: 2009 May |
Date Detail:
|
Created Date: 2009-04-21 Completed Date: 2009-05-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0376343 Medline TA: J Thorac Cardiovasc Surg Country: United States |
Other Details:
|
Languages: eng Pagination: 1249-57 Citation Subset: AIM; IM |
Affiliation:
|
Division of Cardiac Surgery, Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Md. 21287, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Analysis of Variance Animals Carbolines / pharmacology* Cyclic GMP / metabolism Delayed-Action Preparations / pharmacology Disease Models, Animal Graft Rejection Graft Survival Immunohistochemistry Lung Transplantation / adverse effects*, methods Phosphodiesterase Inhibitors / pharmacology* Preoperative Care Probability Rabbits Random Allocation Reactive Oxygen Species / metabolism Reference Values Reperfusion Injury / drug therapy*, prevention & control Tissue and Organ Harvesting / methods* |
| Grant Support | |
ID/Acronym/Agency:
|
2T32DK007713-12/DK/NIDDK NIH HHS; P50HL084946/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Carbolines; 0/Delayed-Action Preparations; 0/Phosphodiesterase Inhibitors; 0/Reactive Oxygen Species; 0/tadalafil; 7665-99-8/Cyclic GMP |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Enhanced fibrinolysis protects against lung ischemia-reperfusion injury.
Next Document: Prevalence of significant peripheral artery disease in patients evaluated for percutaneous aortic va...